Sungen: Bispecific Antibody, Bispecific Antibody Companies

Sungen Biomedical was founded in 2019 which is an innovative antibody drug research and development enterprise incubated by Hotgen Biotech (SH688068), a listed company on the Shanghai Stock Exchange. The co-founder of Sungen Biomedical is Professor Zhiwei Sun, Vice Chairman of China Monoclonal Antibody Industry Committee.

Learn More About Us 

What Does Sungen Achieve?

Sungen Biomedical, founded in 2019 and incubated by Hotgen Biotech, specializes in innovative antibody drugs and large molecule biopharmaceuticals. With a robust R&D pipelines, cutting-edge technology platforms, and strategic collaborations, we are committed to advancing medical science and improving patient outcomes globally.

Explore Sungen Research Innovation 

Technological Platforms

Innovation Achievements

Scientific Frontiers

Sungen News

View all articles 

Jan

2026China FIC Innovation & Collaboration Sumit

TIME: Sunday, Jan 11,2026ADDRESS: Hyatt Regency San Francisco Downtown SOMA Keynote Speech: High-Quality Clinical Trials Underpinning Innovative Drug Developmeng: Development of SGC001, the First-in-W...

Read article >

Jan

Sungen to Showcase China's Innovative Power at JPM 2026

The 44th J.P. Morgan Healthcare Conference (JPM 2026), the world's premier healthcare partnership and investment forum, will convene in San Francisco from January 12 to 15, 2026. Beijing Sungen Bi...

Read article >

Nov

First Show Vienna! Phase I Clinical Data of the World's First Antibody Drug SGC001 for Acute Myocardial Infarction Unveiled BIO Europe2025

On November 3, 2025, Vienna time, Sungen announced the Phase I clinical results of SGC001 Injection, the world's first antibody drug for acute myocardial infarction, at the 31st BIO Europe 2025, h...

Read article >